Pay in 4 interest-free payments of $6.85 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
** In-office visits may be required based on the discretion of your provider
Key Points Summary Asias GLP1 uptake has lagged the West but is primed for rapid acceleration as obesity rates rise and government urgency grows China and India are driving demand shifts as diets westernise and metabolic disease climbs Cost barriers are falling: local firms in China and India are developing cheaper semaglutide generics, forcing price cuts Mintel forecasts explosive growth, with China potentially becoming the worlds No1 GLP1 market by 2030 Safety fears persist in China (side effects, rebound, semaglutide face) and in India (strict rules on drug promotion) GLP-1 agonist drugs have revolutionised weight loss in the United States and parts of Europe, providing in most cases a highly effective way to manage the ballooning issue of obesity in these markets
That pairing is a deliberate one, and it follows directly from the biology above: Akkermansia makes acetate and propionate, and the butyrate producers are the partners that turn that into butyrate
Obesity Silver Spring
Thirteen (12.5%), eight (7.7%), and nine (8.7%) adverse events were reported during 3 months, 6 months, and 1 year of combination treatment, respectively
